Literature DB >> 9124796

Ocular muscle involvement by myasthenia gravis.

H J Kaminski, R L Ruff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9124796     DOI： 10.1002/ana.410410402

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  5 in total

1.  A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.

Authors:  S Gattenlöhner; H Jörissen; M Huhn; A Vincent; D Beeson; S Tzartos; A Mamalaki; B Etschmann; H K Muller-Hermelink; E Koscielniak; S Barth; A Marx
Journal:  J Biomed Biotechnol       Date:  2010-02-24

2.  John Newsom-Davis: clinician-scientist and so much more.

Authors:  Angela Vincent
Journal:  Brain       Date:  2011-12       Impact factor: 13.501

3.  Response to treatment of myasthenia gravis according to clinical subtype.

Authors:  Tetsuya Akaishi; Yasushi Suzuki; Tomihiro Imai; Emiko Tsuda; Naoya Minami; Yuriko Nagane; Akiyuki Uzawa; Naoki Kawaguchi; Masayuki Masuda; Shingo Konno; Hidekazu Suzuki; Hiroyuki Murai; Masashi Aoki; Kimiaki Utsugisawa
Journal:  BMC Neurol       Date:  2016-11-17       Impact factor: 2.474

4.  Extraocular muscle function is impaired in ryr3 -/- mice.

Authors:  Francesco Zorzato; Susan Treves; Jan Eckhardt; Christoph Bachmann; Marijana Sekulic-Jablanovic; Volker Enzmann; Ki Ho Park; Jianjie Ma; Hiroshi Takeshima
Journal:  J Gen Physiol       Date:  2019-05-13       Impact factor: 4.086

5.  Extraocular muscle characteristics related to myasthenia gravis susceptibility.

Authors:  Rui Liu; Hanpeng Xu; Guiping Wang; Jie Li; Lin Gou; Lihua Zhang; Jianting Miao; Zhuyi Li
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.